Conflict of interest: Professor Rozenman has received consulting or lecture fees from Abbott Vascular, Boston Scientific, Medtronic, Pfizer, Sanofi-Aventis, Merck, Eli-Lilly, and AstraZeneca. Drs. Mehran and Dangas have received grant support from BMS/Sanofi-Aventis, consulting or lecture fees from Cordis and The Medicines Company, and serve on Advisory Boards for Abbott Vascular, Cardiva, and Regado Biosciences. Dr. Witzenbichler has received lecture fees from The Medicines Company and Boston Scientific. Dr. Stone serves on Advisory Boards for Abbott Vascular and Boston Scientific and has received consulting fees from The Medicines Company, Eli Lilly, Merck, AstraZeneca, and Bristol-Meyers-Squibb. The other authors have no financial disclosures to report.
Coronary Artery Disease
Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction†
Article first published online: 17 APR 2012
Copyright © 2012 Wiley Periodicals, Inc.
Catheterization and Cardiovascular Interventions
Volume 81, Issue 1, pages E9–E14, 1 January 2013
How to Cite
Rozenman, Y., Mehran, R., Witzenbichler, B., Dangas, G., Desaga, M., Kochman, J., Nilsen, D. W., Finkelstein, A., Mosseri, M. and Stone, G. W. (2013), Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction. Cathet. Cardiovasc. Intervent., 81: E9–E14. doi: 10.1002/ccd.24279
- Issue published online: 21 DEC 2012
- Article first published online: 17 APR 2012
- Manuscript Accepted: 25 NOV 2011
- Manuscript Revised: 16 JUL 2011
- Manuscript Received: 23 MAY 2011
- 22ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006; 47: e1–e121., , , et al.